The best news from Togo on business and economy
Provided by AGP
QGEN SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Qiagen for Possible Securities Law Violations
Qiagen's CFO projected 6% full-year QuantiFERON growth on February 5, 2026. Actual Q1 2026 volumes declined and the company is now projecting sales to remain steady at $500 million
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Qiagen (NASDAQ: QGEN) investors lost approximately 10% of their share value after the company slashed FY 2026 sales-growth guidance from "at least 5% CER" to just 1-2% CER and cut adjusted diluted EPS guidance to at least $2.43 from a prior floor of $2.50 CER. Shareholders who lost money on QGEN are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
On February 5, 2026, CFO Roland Sackers told investors on the Q4 2025 earnings call: "We expect QuantiFERON to grow at a low single-digit CER rate in the first quarter of 2026 … a normalized full-year run-rate for ‘26 of about 6% CER growth." On the same call, CEO Thierry Bernard stated: "We are on track to achieve our '28 goal for at least $2 billion in combined sales from these products." Weeks later, actual Q1 2026 QuantiFERON test volumes showed a 5% CER decline year-over-year. The company then cut full-year sales-growth guidance to 1-2% CER and lowered adjusted diluted EPS to at least $2.43.
The gap between what management projected and what materialized was stark. The “low single-digit CER rate” growth projection for QuantiFERON in Q1 became a 5% decline. The "at least 5% CER" company-wide sales growth outlook was reduced to 1-2% CER. The adjusted EPS floor dropped from $2.50 to $2.43. Levi & Korsinsky is investigating whether Qiagen's officers possessed information about weakening QuantiFERON demand at the time these projections were made.
If you purchased Qiagen shares and suffered a loss, click here to discuss your legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the QGEN Investigation
Q: How much did QGEN stock drop? A: Shares fell more than 10%. From a closing price of $38.09 on April 27, 2026, QGEN stock closed at $34.02 on April 28, 2026, a $4.07 drop.
Q: What specific misstatements are being investigated? A: The QGEN investigation concerns statements made by the company and its management regarding its sales-growth outlook, QuantiFERON TB test demand, its debt classification, and the adequacy of its non-GAAP financial disclosures during the class period. When the true state was revealed, the stock price declined sharply.
Q: What do QGEN investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible as a class member in any potential suit.
Q: What if I already sold my QGEN shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the determined class period and sold at a loss may still participate.
Q: What does it cost me to participate? A: Nothing. Securities investigations and the potential resultant class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. This is currently just an investigation. Even if a suit is filed, however, the overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: Has Levi & Korsinsky handled similar cases before? A: Yes, including securities class actions involving revenue inflation, earnings guidance fraud, dividend misrepresentation, and executive misconduct across numerous industries.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
